Oliviero James F III 4

What Happened James F. Oliviero III, a director of Nuvectis Pharma, received a grant of 35,000 shares of restricted common stock on 2026-06-11. The shares were granted at $0.00 per share (total cash purchase price $0) and reported on a Form 4 filed 2026-06-12. Transaction code: A (award/grant).

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (timely filing).
• Grant size and price: 35,000 shares of restricted common stock at $0.00.
• Shares owned after transaction: Not disclosed in the filing.
• Footnotes: (F1) The 35,000 shares vest in equal annual installments over three years beginning on the first anniversary of the grant, subject to continued board service. (F2) The reported shares are restricted common stock.
• No 10b5-1 plan, tax-withholding sale, or sale activity was indicated.

Context This was a restricted-stock award to a board member, not an open-market purchase or sale. The shares vest over three years, so they are subject to forfeiture if Mr. Oliviero stops serving on the board before vesting. Awards at $0 are common compensation practices and do not by themselves indicate a buy or sell market signal.